With this collaboration, Kemwell will complement their early clinical supply services, ranging from full-service process development, manufacture, formulation and fill & finish at the cGMP manufacturing facility in Bangalore, India, as a one-stop-shop through access to Boehringer Ingelheim's cell line development with the BI HEX technology platform, followed by a preferred access to the large-scale commercial production of Boehringer Ingelheim at its facilities in Europe.

Every time Boehringer Ingelheim is able to rapidly recover from a fault, it saves literally hundreds of hours of staff productivity.

Boehringer Ingelheim and FDA issued an Early Communication to notify health care professionals that ongoing safety monitoring has identified a possible increased risk of stroke in patients who take Spiriva.